ReviewCurrent hematologic malignancy reports2015
Treating Burkitt Lymphoma in Adults.
Review in Current hematologic malignancy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Burkitt and Burkitt-Like Lymphomas: a Systematic Review.Current oncology reports · 2020Pooled it
- Anti-tumor activity of valproic acid in EBV-positive Burkitt lymphoma via PFN2-associated PI3K/AKT pathway repression.Frontiers in pharmacology · 2026Article
- Outcomes of critically ill patients with newly diagnosed Burkitt's lymphoma: a monocentric retrospective study.Annals of intensive care · 2026Article
- Burkitt lymphoma after adult liver transplantation: a case report and literature review.Frontiers in oncology · 2024Article
- EBV-Related Lymphoproliferative Diseases: A Review in Light of New Classifications.Mediterranean journal of hematology and infectious diseases · 2024Review
- Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt's lymphoma: a case report.Translational cancer research · 2022Article
- A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word multicenter study.BMC cancer · 2022Article
- [Effects of L-asparaginase on proliferation, cell cycle and apoptosis of Burkitt lymphoma cell lines].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Review
- Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma.Cancer biology & medicine · 2021Article
- Review
- Mandibular sporadic Burkitt lymphoma in an adult patient: A case report and review of the literature.Clinical case reports · 2021Article
- Triclosan induces apoptosis in Burkitt lymphoma-derived BJAB cells through caspase and JNK/MAPK pathways.Apoptosis : an international journal on programmed cell death · 2021Article
- Nicotinamide adenine dinucleotide phosphate oxidase inhibitor induces apoptosis on Epstein-Barr virus positive B lymphoma cells.Anatomy & cell biology · 2020Article
- Inhibition of HIF-1α by Atorvastatin DuringCancers · 2020Article
- Inferior prognosis of gastric involvement in patients with gastrointestinal Burkitt Lymphoma.Cancer medicine · 2020Article
- Role and mechanism of PTEN in Burkitt's lymphoma.Oncology reports · 2020Article
- JNK/AP1 Pathway Regulates MYC Expression and BCR Signaling through Ig Enhancers in Burkitt Lymphoma Cells.Journal of Cancer · 2020Article
- Intestinal atresia following chemotherapy, presenting as superior mesenteric artery syndrome: A case report.Molecular and clinical oncology · 2017Article
- Intraoral EBV-positive sporadic Burkitt lymphoma in an elderly patient with bilateral presentation.Autopsy & case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkitt lymphoma is an uncommon form of aggressive lymphoma affecting approximately 1200 patients per year in the USA. It is characterized by a translocation involving the MYC oncogene. Three subtypes of Burkitt lymphoma are recognized: the endemic form, occurring primarily in Africa and associated with the Epstein-Barr virus (EBV); the sporadic form, representing less than 3 % of all non-Hodgkin lymphomas (NHL); and the immunodeficiency-associated form, occurring primarily in HIV-infected patients. Burkitt lymphoma appears histologically with a diffuse pattern of intermediate-sized monomorphic B cells, multiple nucleoli, a very high proliferative rate, and frequent mitotic figures. Recent advances in transcriptional profiling have improved the current molecular understanding of Burkitt lymphoma and have better characterized its mutational landscape. Most Burkitt lymphoma patients are cured with intensive treatment; however, prognosis is poor in elderly patients and those with relapsed disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.